Mapatumumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Mapatumumab" in English language version.

Last modified: 21:40:01, 20 December 2023 (UTC)

Ref.Un. Ref.Website

Global rank English rank

86hgsi.com

low place

33nih.gov

5^th place

22doi.org

2^nd place

11ama-assn.org

4,430^th place

4,511^th place

11semanticscholar.org

15^th place

8^th place

11web.archive.org

1^st place

11businessweek.com

945^th place

628^th place

ama-assn.org (Global: 4,430^th place; English: 4,511^th place)

Statement On A Nonproprietary Name Adopted By The Usan Council - Mapatumumab, American Medical Association.

businessweek.com (Global: 945^th place; English: 628^th place)

"Human Genome Sciences says cancer drug fails study". bloomberg.com. June 9, 2010. Archived from the original on October 24, 2012.

doi.org (Global: 2^nd place; English: 2^nd place)

Moretto P, Hotte SJ (March 2009). "Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1". Expert Opinion on Investigational Drugs. 18 (3): 311–25. doi:10.1517/13543780902752463. PMID 19243282. S2CID 71176481.
Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, et al. (April 2005). "HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo". British Journal of Cancer. 92 (8): 1430–41. doi:10.1038/sj.bjc.6602487. PMC 2361994. PMID 15846298.

hgsi.com (Global: low place; English: low place)

"Human Genome Sciences reports results of ongoing phase 1 clinical trials of HGS-ETR1 in patients with advanced cancers". Human Genome Sciences. September 29, 2004. Retrieved August 7, 2009.{{cite web}}: CS1 maint: deprecated archival service (link)
"Human Genome Sciences reports results of phase 2 clinical trial of HGS-ETR1 in patients with non-small-cell lung cancer". Human Genome Sciences. July 5, 2005. Retrieved August 7, 2009.{{cite web}}: CS1 maint: deprecated archival service (link)
"Human Genome Sciences reports results of phase 2 clinical trial of HGS-ETR1 in patients with advanced colorectal cancer". Human Genome Sciences. November 1, 2005. Retrieved August 7, 2009.{{cite web}}: CS1 maint: deprecated archival service (link)
"Human Genome Sciences reports interim results of phase 1B clinical trials of HGS-ETR1 in combination with chemotherapy in patients with advanced solid tumors". Human Genome Sciences. November 17, 2005. Retrieved August 7, 2009.{{cite web}}: CS1 maint: deprecated archival service (link)
"Human Genome Sciences reports results of phase 2 clinical trial of HGS-ETR1 in patients with advanced non-Hodgkin's lymphoma". Human Genome Sciences. December 13, 2005. Retrieved August 7, 2009.{{cite web}}: CS1 maint: deprecated archival service (link)
"Human Genome Sciences reports initial results of randomized phase 2 clinical trial of HGS-ETR1 in combination with bortezomib in advanced multiple myeloma". Human Genome Sciences. September 2, 2008. Retrieved August 7, 2009.{{cite web}}: CS1 maint: deprecated archival service (link)

nih.gov (Global: 5^th place; English: 5^th place)

pubmed.ncbi.nlm.nih.gov

Moretto P, Hotte SJ (March 2009). "Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1". Expert Opinion on Investigational Drugs. 18 (3): 311–25. doi:10.1517/13543780902752463. PMID 19243282. S2CID 71176481.
Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, et al. (April 2005). "HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo". British Journal of Cancer. 92 (8): 1430–41. doi:10.1038/sj.bjc.6602487. PMC 2361994. PMID 15846298.

ncbi.nlm.nih.gov

Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, et al. (April 2005). "HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo". British Journal of Cancer. 92 (8): 1430–41. doi:10.1038/sj.bjc.6602487. PMC 2361994. PMID 15846298.

semanticscholar.org (Global: 15^th place; English: 8^th place)

api.semanticscholar.org

Moretto P, Hotte SJ (March 2009). "Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1". Expert Opinion on Investigational Drugs. 18 (3): 311–25. doi:10.1517/13543780902752463. PMID 19243282. S2CID 71176481.

web.archive.org (Global: 1^st place; English: 1^st place)

"Human Genome Sciences says cancer drug fails study". bloomberg.com. June 9, 2010. Archived from the original on October 24, 2012.

Mapatumumab (English Wikipedia)

ama-assn.org (Global: 4,430th place; English: 4,511th place)

businessweek.com (Global: 945th place; English: 628th place)

doi.org (Global: 2nd place; English: 2nd place)